Seiji Okada

Fourth-generation chimeric antigen receptor T cells targeting mucin 1 for enhanced anti-tumor activity against breast cancer

Breast cancer (BC) is the leading cause of cancer-related mortality worldwide, and current treatments are unmet clinical needs. Although chimeric antigen receptor (CAR) T cells have been approved for hematological malignancies, their advancements in solid tumors are challenging....